Zhengye Biotechnology Holding Stock
Zhengye Biotechnology Holding Limited
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- China
- CEO
- Songlin Song
- Employees
- 269
- Market cap
- $66 M
- IPO
- 07/01/2025
Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry.…
Zhengye Biotechnology Holding stock: price history
1D
-6.7%
1W
-19.1%
1M
+2.2%
6M
+41.3%
YTD
+21.7%
1Y
-45.3%
2Y
–
5Y
–
10Y
–
Ask the agents about Zhengye Biotechnology Holding
Zhengye Biotechnology Holding stock metrics
P/E
-4.83
P/B
1.78
EV/EBITDA
-9.43
RETURN ON EQUITY
-18.9%
NET MARGIN
-89.0%
DEBT/EQUITY
0.3
DIVIDEND YIELD
0.0%
AS OF
31/12/2025
Free float & liquidity
FREE FLOAT
9.3%
FLOAT SHARES
4,427,634
AVG. DAILY VOLUME (30D)
1,166,268
Institutional holders
Comparable stocks
Frequently asked questions about Zhengye Biotechnology Holding stock
What does Zhengye Biotechnology Holding do?
Zhengye Biotechnology Holding Limited is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in China.
The CEO is Songlin Song, the company employs around 269 people.
The IPO was on 07/01/2025; the stock trades on NASDAQ under the ticker ZYBT.
Does Zhengye Biotechnology Holding pay a dividend?
No, Zhengye Biotechnology Holding currently does not pay a dividend.
Which stocks are comparable to Zhengye Biotechnology Holding?
Comparable stocks include Merck, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.
How can I get Zhengye Biotechnology Holding stock analyzed?
Clicking "Analyze stock" lets five strategies assess Zhengye Biotechnology Holding against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.